Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  News  >  Companies  >  All News

News : Companies

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance ProfessionalsCalendarSectors

PTC Therapeutics Inc. : PTC THERAPEUTICS PRICES INITIAL PUBLIC OFFERING

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/21/2013 | 11:03am CET

SOUTH PLAINFIELD, NJ - June 20, 2013 - PTC Therapeutics, Inc. (PTC) today announced the pricing of its initial public offering of 8,372,000 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts. All of the shares in the offering are being sold by PTC. In addition, the underwriters have an option for a period of 30 days to purchase up to 1,255,800 additional shares of common stock from PTC at the public offering price, less the underwriting discount. PTC's common stock has been approved for listing on the NASDAQ Global Select Market and is expected to begin trading under the ticker symbol "PTCT" on June 20, 2013.

J.P. Morgan and Credit Suisse are acting as joint book-running managers for the offering. Cowen and Company is acting as co-lead manager and Wedbush PacGrow Life Sciences as co-manager.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on June 19, 2013.

The offering is being made only by means of a prospectus, copies of which may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717; telephone: 866-803-9204; or Credit Suisse Securities (USA) LLC, Attn: Prospectus Department, One Madison Avenue, New York, NY 10010; telephone: 800-221-1037; email: [email protected]

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

ABOUT PTC THERAPEUTICS, INC.

PTC is a biopharmaceutical company focused on the discovery and development of orally administered small-molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare genetic disorders and infectious diseases.

CONTACT

Jane Baj

PTC Therapeutics, Inc.

908-912-9167

[email protected]

Sheryl Seapy

Pure Communications

[email protected]


distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news "Companies"
08:24a ARRIS INTERNATIONAL PLC : Regulation FD Disclosure (form 8-K)
08:24a BOEING : Airworthiness Directives; The Boeing Company Airplanes
08:24a MARICANN : IIROC Trading Halt - MARI
08:24a KALVISTA PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)
08:24a Early holiday shoppers for consumer electronics did most research, buying online – GfK digital panel
08:23a EBAY : Today’s Research Reports on Trending Tickers: eBay Inc. and Square, Inc.
08:23a $450+ Million Gastrointestinal / GI Stent Market by Type, Materia, Disease, End User - Global Forecast to 2022 - Research and Markets
08:23a YAMANA GOLD INC. : Today’s Research Reports on Trending Tickers: Yamana Gold and Goldcorp Inc.
08:22a BASF : and TODA further strengthen their collaboration and increase investments in Cathode Materials to enable e-mobility
08:22a SKY : Response to Announcement made by 21CF and Disney
Latest news "Companies"
Advertisement